Dafra Pharma

Understanding the malaria cycle is crucial in fighting this disease. The female Anopheles mosquito transmits the Plasmodium parasite when it bites a human. With our antimalarial drugs, we break this cycle in Sub-Saharan Africa. 💊 #MalariaCycle #BreakTheCycle #WorldMalariaDay #PharmaAgainstMalaria #DafraPharma

Today, we mark World Malaria Day, a day dedicated to raising awareness about the global effort to control and eventually eradicate malaria. As a pharmaceutical company that was deeply involved in the research and development of antimalarial drugs in the early 2000s, we are proud of our contribution to combating this deadly disease. Malaria continues to pose a significant threat to millions of lives worldwide, and our commitment to finding effective treatments and solutions remains unwavering. Over the years, we have worked tirelessly to develop innovative and accessible antimalarial drugs, partnering with communities, governments, and global health organizations to ensure that these life-saving treatments reach those who need them most. On this important day, let us reaffirm our collective commitment to ending malaria for good. Prevention, treatment, and elimination require a coordinated and sustained effort from all of us. Together, we can make malaria a thing of the past. #WorldMalariaDay #EndMalaria #DafraPharma

- TT4CL project from Oblita Therapeutics - In the early days of #DafraPharma, the co-founder Dr FH Jansen, a pioneer in artemisinin chemistry, developed new artemisinin combination therapies to treat malaria. Co-artesiane and Co-arinate are still two leading anti-malaria brands, marketed by Dafra Pharma (Bruno Jansen, CEO). Dr Jansen initiated another important development for a very neglected tropical disease : cutaneous leishmaniasis. This research project on the molecule D121 was later acquired by his daughter, Caroline Jansen, in a spin-out Oblita Therapeutics. We are proud to announce D121 now turns out to be a stable and safe oral drug that outcompetes the current standard oral treatment in all preclinical efficacy studies. D121 will soon enter into phase 2. Interested? Please see more in the document below or even better, follow TT4CL.

Looking to add an EU pharmaceutical company that markets medicines and health solutions complying with the highest quality standards to improve the public health in #Africa to your list of company pages? ➡ Dafra Pharma and click the follow button

Wishing all #DafraPharma clients, staff members and partners a happy #NewYear. We thank all our employees for the progress made the past year. As for our customers and business partners, thanks for the mutual trust and respect we have for each other. We look forward to continuing to serve you with fine assistance and effort in #2024.

For the season of joy and thanksgiving, we would like to express our gratitude for our lovely staff and their family this Christmas. May you all have a hearty, festive holiday season. And to our business partners and clients, hope our Christmas trees bear on them the wealth and prosperity that we look forward to in our businesses together. A merry Christmas with warm wishes from the entire #DafraPharma team.